RPL36AP8: A Ribosomal Protein L36a Pseudogene as a Drug Target and Biomarker

Target Name: RPL36AP8

NCBI ID: G643007

RPL36AP8

Other Name(s): ribosomal protein L36a pseudogene 8 | RPL36A_20_1424 | Ribosomal protein L36a pseudogene 8

RPL36AP8: A Ribosomal Protein L36a Pseudogene as a Drug Target and Biomarker

Introduction

Ribosomal protein (RPN) L36a pseudogene 8 (RPL36AP8) is a gene that encodes a protein involved in the replication process in eukaryotic cells. The RPN L36a pseudogene is one of the genes that encode the ribosomal protein L36a (RPL36), which is a key component of the ribosome, the site of protein synthesis in eukaryotic cells.

Recent studies have identified RPL36AP8 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential clinical applications of RPL36AP8.

Biography of RPL36AP8

RPL36AP8 is a pseudogene, which means that it is a non-coding gene that encodes a protein. The gene is derived from the genomic sequence of the human nuclear DNA. RPL36AP8 is located on chromosome 19 at position 181.368 GHz.

The protein encoded by RPL36AP8 is a 21-kDa protein that contains 114 amino acid residues. The protein has a calculated pI of 5.5 and a predicted localization in the cytoplasm.

Expression of RPL36AP8

RPL36AP8 is expressed in most tissues of the body, including muscle, pancreas, heart, kidney, and brain. The protein is predominantly expressed in the cytoplasm and is also observed in the endoplasmic reticulum (ER) and the mitochondria.

Function of RPL36AP8

RPL36AP8 is involved in the replication process in eukaryotic cells. It functions as a protein of the ribosome, where it is involved in the formation of the initiation complex, which is the first step in the process of protein synthesis.

The RPL36AP8 protein has been shown to play a critical role in the initiation complex. It is one of the components of the S1 initiation complex, which is responsible for the recruitment of the small subunit of the ribosome (S1) to the ribosome and the formation of the initiation complex.

In addition to its role in the initiation complex, RPL36AP8 has also been shown to be involved in the regulation of protein synthesis. It has been shown to interact with the factors that regulate protein synthesis, such as the factors that bind to the A-site of the ribosome.

Potential clinical applications of RPL36AP8

RPL36AP8 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1.Cancer

RPL36AP8 has been shown to be involved in the regulation of cell proliferation, which is a critical step in the development of cancer. It has been shown to play a role in the regulation of the G1/S transition, which is a critical step in the cell cycle that determines the growth and differentiation of cells.

In addition to its role in cell proliferation, RPL36AP8 has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die as a result of various factors, including DNA damage, UV radiation, and infection.

2. Neurodegenerative diseases

RPL36AP8 has been shown to be involved in the regulation of the neurotransmitter synthesis and release, which is a critical step in the development of neurodegenerative diseases. It has been shown to play

Protein Name: Ribosomal Protein L36a Pseudogene 8

The "RPL36AP8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36AP8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets